Background & Aims Previous studies have identified a substantial degree of agreement between the non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) populations, but the same notion may not apply to normal-weight patients with a lower cardiometabolic risk burden. This study aims to investigate the CMRF distributions between normal-weight and overweight/obese MASLD, the agreement between historical NAFLD and MASLD, and to compare the risk of liver-related events (LREs) and all-cause mortality in normal-weight versus overweight or obese MASLD.
Methods This study included participants with steatotic liver disease (SLD) from five cohorts in Hong Kong, South Korea, and the United States. Participants were recruited from settings including both hospitals and communities. Individuals were classified into normal-weight and overweight/obese groups.
Results This study included 33,793 participants with SLD from five cohorts, of whom 20,893 and 20,701 patients met the diagnosis of NAFLD and MASLD, respectively. Normal-weight patients with NAFLD demonstrated a lower CMRF distribution compared to those with overweight/obese NAFLD. In the community-based cohorts, the proportions of 0 CMRF ranged from 9.0-26.7% among normal-weight NAFLD, representing the discrepancy between MASLD and NAFLD definitions. Compared with the overweight/obese MASLD, the normal-weight MASLD had increased all-cause mortality (normal-weight vs. overweight/obese, 23.44 and 13.80 per 1000 person-years; p<0.001) but not LREs (2.81 and 2.59 per 1000 person-years; p=0.54) in the HK CDARS cohort.
Conclusions Normal-weight individuals with NAFLD demonstrated a lower distribution of CMRFs, resulting in the incomplete agreement between historical NAFLD and MASLD.
Ethical Compliance For all involved cohorts, the study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were approved by the appropriate clinical research ethics committee and/or institutional review board, which provided either written consent or a waiver of informed consent.
Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Grace Lai-Hung Wong, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):353-367. Published online December 1, 2025
Background/Aims Previous studies suggest that hypothyroidism is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and its histological severity, but clinical outcome data are largely lacking. We aimed to study the impact of hypothyroidism on liver-related events (LREs).
Methods Patients with MASLD were identified from a territory-wide registry in Hong Kong during 2000–2024. Thyroid status was determined using diagnosis codes and thyroid function tests. The primary outcome, LRE, was defined as a composite of hepatic decompensation, hepatocellular carcinoma, liver transplantation, and liver-related death.
Results A total of 20,478 patients with MASLD were included in the final analysis (mean age 56.4±13.2 years; 43.9% male). At baseline, 18,178 (88.8%) patients were euthyroid, 598 (2.9%) were hyperthyroid, and 1,702 (8.3%) were hypothyroid. Compared with euthyroid patients, both hyperthyroidism and overt hypothyroidism were associated with cirrhosis. At a median follow-up of 4.8 years, 179 patients developed LREs, and 26 died from liver disease. Compared with patients with normal serum thyroid-stimulating hormone (TSH) levels of 0.4–4 mIU/L, those with subclinical (4–10 mIU/L; adjusted time-dependent cause-specific hazard ratio [aCSHR], 2.49; 95% CI, 1.51–4.13) and overt hypothyroidism (>10 mIU/L; aCSHR, 4.91; 95% CI, 1.56–15.47) had an increased risk of LREs. Time-dependent, but not baseline, TSH and thyroid status were associated with LRE risk.
Conclusions Subclinical and overt hypothyroidism are associated with an increased risk of LREs in a dose-dependent manner. The association with time-dependent but not baseline thyroid status underscores the importance of thyroid monitoring and suggests that correction of hypothyroidism may mitigate LRE risk.
Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):289-304. Published online November 11, 2025
Background/Aims Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Results F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Background/Aims Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus. The purpose of this assessment was to establish proof of concept in liver histologic improvement with HTD1801 treatment based on preclinical and clinical evidence.
Methods The efficacy of HTD1801 was evaluated in a preclinical MASH/dyslipidemia model (golden hamsters fed a high fat diet, eight/group) after six weeks of daily treatment. Additionally, in a secondary analysis of a Phase 2 clinical study, 100 patients with presumed MASH were evaluated by multiple noninvasive markers associated with MASH resolution and/or fibrosis improvement. These include magnetic resonance imaging proton density fat fraction (MRIPDFF; ≥30% LFC reduction), iron-corrected T1 (≥80 ms reduction), alanine aminotransferase (≥17 U/L reduction), weight loss (≥5% reduction), Fibrosis-4 index (shift to <1.3), and MASH resolution index (achieving ≥–0.67).
Results Preclinical findings in the MASH/dyslipidemia hamster model showed that HTD1801 significantly improved histologic fibrosis and the Nonalcoholic Fatty Liver Disease Activity Score to such a degree that improvements approximated the appearance of the normal controls. In the clinical study, 52% of HTD1801-treated patients achieved MRI response criteria compared to 24% of placebo (p<0.05). Dose-dependent improvements were observed across biomarkers, with more HTD1801-treated patients achieving response criteria associated with improvements in the histologic features of MASH.
Conclusions These findings suggest that HTD1801 has strong potential to produce histological improvements in patients with MASH.
Citations
Citations to this article as recorded by
Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease Chengyun Ma, Jing Wang, Xuanli Song, Xue Wang, Shuai Zong Frontiers in Immunology.2025;[Epub] CrossRef
Activation of Sirtuin 3, a Promising “Head Goose Molecule,” Triggers the Negentropic Mechanism for Treating Metabolic Diseases Hu Li, Tong Wang, Biao Dong, Zonggen Peng, Jiandong Jiang Engineering.2025;[Epub] CrossRef
Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys Jung Hwan Yu, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(1): e52. CrossRef
Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti Diabetes Research and Clinical Practice.2025; 229: 112465. CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299. CrossRef
CXCL12 as a Potential Hub Gene for N-Acetylcysteine Treatment of T1DM Liver Disease Menglong Zhao, Mingzheng Han, Shuaihao Guo, Zhaoxin Tang Biomolecules.2025; 15(2): 176. CrossRef
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue Cancer Science.2025;[Epub] CrossRef
In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related complications, and assessing treatment response are crucial. The advantage of simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests and extensive validation in different clinical settings. They have shown reasonable accuracy in diagnosing advanced fibrosis and good performance in excluding the majority of patients with a low risk of liver-related complications. Among patients with elevated serum fibrosis scores, a more specific fibrosis and imaging biomarker has proved useful to accurately identify patients at risk of liver-related complications. Among specific fibrosis blood biomarkers, enhanced liver fibrosis is the most widely utilized and has been approved in the United States as a prognostic biomarker. For imaging biomarkers, the availability of vibration-controlled transient elastography has been largely improved over the past years, enabling the use of liver stiffness measurement (LSM) for accurate assessment of significant and advanced fibrosis, and cirrhosis. Combining LSM with other routinely available blood tests enhances the ability to diagnose at-risk metabolic dysfunction-associated steatohepatitis and predict liver-related complications, some reaching an accuracy comparable to that of liver biopsy. Magnetic resonance imaging-based modalities provide the most accurate quantification of liver fibrosis, though the current utilization is limited to research settings. Expanding their future use in clinical practice depends on factors such as cost and facility availability.
Citations
Citations to this article as recorded by
Fe-Mn-IGF-AMD nanoparticles in accurate detection and treatment of liver cirrhosis via regulating relaxation coefficients and attenuating hepatocyte senescence Baihe Wang, Tingting Ji, Zihao Zhang, Yuyao Duan, Zhiqun Xing, Jiazhi Duan, Songbo Zhao, Yang Jia, Qian Wang Colloids and Surfaces B: Biointerfaces.2026; 257: 115182. CrossRef
Stimuli-responsive nanomedicines for hepatic diseases: mechanism, design, recent advances, and clinical translation Leyi Wang, Xue Zhang, Yinggang Li, Min Zhao, Gang Xu, Zhenyu Duan, Qiyong Gong, Kui Luo Journal of Controlled Release.2026; 390: 114522. CrossRef
Prediction of major liver-related events in the population using prognostic models Fredrik Åberg, Ville Männistö Gastroenterology Report.2025;[Epub] CrossRef
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, David Martí-Aguado, Desamparados Escudero, Marta Cedenilla Journal of Clinical Medicine.2025; 14(7): 2441. CrossRef
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease Jimmy Che-To Lai, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel A Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jerome Boursier, Jose Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocìo Gallego-Du Gut.2025; 74(12): 2050. CrossRef
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD Yu Shi, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Calleja, Victo Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng Gut.2025; 74(10): 1741. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Endohepatology in the Management of Liver Diseases Thomas J. Wang, Ajaypal Singh Seminars in Liver Disease.2025; 45(04): 439. CrossRef
Letter to the Editor: Are we overestimating LSM-based HCC risk in MASLD? Addressing immortal time bias Heechul Nam, Sung Won Lee Hepatology.2025;[Epub] CrossRef
Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions Said A. Al-Busafi, Mohammed Eslam Transplantology.2025; 6(4): 35. CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon Clinical and Molecular Hepatology.2024; 30(2): 247. CrossRef
Background/Aims Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients.
Methods We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment.
Results We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all p≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, p<0.0001).
Conclusions IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.
Citations
Citations to this article as recorded by
Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie Journal of Viral Hepatitis.2026;[Epub] CrossRef
Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune Archives of Virology.2026;[Epub] CrossRef
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong Clinical and Molecular Hepatology.2026; 32(1): 429. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnostic value of transient elastography in assessing the degree of liver fibrosis in chronic hepatitis B patients with low alanine aminotransferase levels and concomitant hepatic steatosis Aili Wang, Qingqing Wang, Huaie Liu Saudi Journal of Gastroenterology.2026;[Epub] CrossRef
Obesity management for the hepatologist—What to do, how to do it and why? Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, Mohammad Siddiqui, Jenny Lam, Tayyab S. Diwan, Michael Camilleri Hepatology.2025; 81(5): 1607. CrossRef
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao American Journal of Gastroenterology.2025; 120(2): 401. CrossRef
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao Cancer.2025;[Epub] CrossRef
Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history Wen-Jie Liu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu Journal of Gastroenterology.2025; 60(1): 107. CrossRef
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao Journal of Hepatology.2025; 83(1): 43. CrossRef
The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines Grace Lai-Hung Wong, Maud Lemoine Journal of Hepatology.2025; 82(5): 918. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao The Journal of Infectious Diseases.2025; 232(2): 474. CrossRef
Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, Frank Mulindwa, Mackenzie G. Cater, Robert A. Salata, Jeffrey M. Jacobson Frontiers in Immunology.2025;[Epub] CrossRef
Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID) Zhenqiu Liu, Yanfeng Jiang, Chen Suo, Huangbo Yuan, Ziyu Yuan, Tiejun Zhang, Li Jin, Xingdong Chen International Journal of Epidemiology.2025;[Epub] CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo Journal of Hepatology.2025; 83(2): 502. CrossRef
Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, Fernando Bessone, Margarita Anders, Mario G. Pessoa, Fernando Cairo, D Journal of Viral Hepatitis.2025;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats Clinical and Molecular Hepatology.2025; 31(3): 1003. CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, J Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy Yu Jun Wong Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, Carmen Chak-Lui Wong, Valerie Chew, Bryan Cho Wing Li, Roland Leung, Tan To Cheung, Thomas Yau Liver Cancer.2025; : 1. CrossRef
Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review Rushi V. Mukkawar, Nishant Rathod, Rajvardhan Patil, Sunil Kumar, Sourya Acharya International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 368. CrossRef
Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun Cancers.2025; 18(1): 120. CrossRef
Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise? Xiaoming Xu, Mindie H. Nguyen, Jie Li Clinical Gastroenterology and Hepatology.2024; 22(9): 1956. CrossRef
Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study Shanshan Qin, Jing Wang, Haiqing Yuan, Jingzhen He, Shoujing Luan, Yan Deng Frontiers in Genetics.2024;[Epub] CrossRef
The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy Frontiers in Gastroenterology.2024;[Epub] CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert J. de Knegt, Qiuwei Pan Hepatology International.2024; 18(3): 1053. CrossRef
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Journal of Gastroenterology and Hepatology.2024; 39(6): 1190. CrossRef
Impact of metabolic disorders on chronic hepatitis B Shang-Chin Huang, Chun-Jen Liu, Jia-Horng Kao Clinical Liver Disease.2024;[Epub] CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef
Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database David Uihwan Lee, Kuntal Bhowmick, Sindhura Kolachana, Kimberly Schuster, Aneesh Bahadur, Ashton Harmacinski, Sophie Schellhammer, Gregory Hongyuan Fan, Ki Jung Lee, Catherine Sun, Hannah Chou, Zurabi Lominadze Digestive Diseases and Sciences.2024; 69(7): 2401. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Exploration of Digestive Diseases.2024; : 175. CrossRef
Liver health in hemophilia in the era of gene therapy Yesim Dargaud, Massimo Levrero, François Bailly, Anne Lienhart, Fabien Zoulim Thrombosis Research.2024; 240: 109064. CrossRef
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong eClinicalMedicine.2024; 74: 102727. CrossRef
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu Hepatology International.2024; 18(S2): 897. CrossRef
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’ Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe Canadian Liver Journal.2024; 7(3): 385. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng World Journal of Hepatology.2024; 16(12): 1395. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B Xianhua Mao, Lung Yi Mak, Wai-Kay Seto Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease Yajing You, Tao Yang, Shuhang Wei, Zongxin Liu, Chenxi Liu, Zijian Shen, Yinuo Yang, Yuemin Feng, Ping Yao, Qiang Zhu Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2283. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
Persistent steatosis correlates with decreased fibrosis regression during anti‐HBV treatment in patients with chronic HBV infection Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong, Gwyneth Shook Ting Soon, Xiaojuan Ou, Jidong Jia, Wei Chen, Yameng Sun, Hong You Journal of Medical Virology.2023;[Epub] CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef
Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho Clinical and Molecular Hepatology.2024; 30(3): 561. CrossRef
Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature and poor correlation with liver biochemical markers. Liver histology keeps its role as the standard tool, yet it is well-known for substantial sampling, intraobserver, and interobserver variability. Serum proinflammatory cytokines and apoptotic markers, namely cytokeratin-18, are well-studied with reasonable accuracy, whereas serum metabolomics and lipidomics have been adopted in some commercially available diagnostic models. Ultrasound and computed tomography imaging techniques are attractive due to their wide availability; yet their accuracies may not be comparable with magnetic resonance imaging-based tools. Machine learning and deep learning models, be they supervised or unsupervised learning, are promising tools to identify various subtypes of NAFLD, including those with dominating liver inflammation, contributing to sustainable care pathways for NAFLD.
Citations
Citations to this article as recorded by
Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018 Ming-yu He, Xin-jie Du, Yi-ming Liu BMC Gastroenterology.2025;[Epub] CrossRef
Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease Yunfei Wu, Yan Han, Liming Zheng, Longgen Liu, Wenjian Li, Fan Zhang BMC Gastroenterology.2025;[Epub] CrossRef
Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta‐Analysis Jinwen Chen, Jian Hu, Jialin Zhuang, Zhong Li, Se Peng, Xiaoting Huang, Jialing Zhuang Journal of Clinical Laboratory Analysis.2025;[Epub] CrossRef
Obesity: pathophysiology and therapeutic interventions Yue Kong, Haokun Yang, Rong Nie, Xuxiang Zhang, Fan Zuo, Hongtao Zhang, Xin Nian Molecular Biomedicine.2025;[Epub] CrossRef
The advanced lung cancer inflammation index has an L-shaped association with prognosis in American adults with metabolic dysfunction-associated fatty liver disease: a cohort study Yuexia Lu, Shuaipeng Yuan, Huazhao Xu, Jiqi Ouyang, Jinsheng Dong, Xin Jiang, Xiao Shao, Runshun Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
Global Trends in Non-Invasive Techniques for the Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease: A Bibliometric and Visualization Analysis Jing-Wen Cai, Wei-Long Wang, Dong-Ling Lin, Shu-Feng Ren, Qian-Qian Jia, Xiao-Xuan He, Xue-Xia Yang, Wen Cai, Hui Hou Journal of Multidisciplinary Healthcare.2025; Volume 18: 4243. CrossRef
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden Clinical Epigenetics.2025;[Epub] CrossRef
Quantification of 18F-FDG Delivery Rate for Liver Inflammation Using Shortened Dynamic PET Imaging Protocols Xiaoyu Duan, Souvik Sarkar, Victoria Lyo, Sean Romeo, Benjamin A. Spencer, Karen E. Matsukuma, Valentina Medici, Michael T. Corwin, Ramsey D. Badawi, Guobao Wang Journal of Nuclear Medicine.2025; 66(11): 1834. CrossRef
ChatGPT improves usability, effectiveness, scalability, interpretability and accessibility, in early diagnosis of metabolic dysfunction-associated fatty liver disease Xiaoying Zhou, Zhipeng Gao, Han Ma, Jiahui Hu, Chengfu Xu, Zhe Shen, Miaomiao Tan, Chaohui Yu BMC Gastroenterology.2025;[Epub] CrossRef
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality Sung Won Lee, Daniel Q. Huang, Ricki Bettencourt, Veeral Ajmera, Monica Tincopa, Nabil Noureddin, Maral Amangurbanova, Harris Siddiqi, Egbert Madamba, Abdul M. Majzoub, Tarek Nayfeh, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Masato Yoneda, Ramzan I Alimentary Pharmacology & Therapeutics.2024; 59(1): 80. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis Marinela Sînziana Tudor, Veronica Gheorman, Georgiana-Mihaela Simeanu, Adrian Dobrinescu, Vlad Pădureanu, Venera Cristina Dinescu, Mircea-Cătălin Forțofoiu Metabolites.2024; 14(4): 198. CrossRef
Editorial: Inflammation and chronic disease Frank A. Orlando, Arch G. Mainous Frontiers in Medicine.2024;[Epub] CrossRef
Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis Shaofang Chen, Danping Zhuang, Qingyun Jia, Bing Guo, Genwen Hu Biomaterials Research.2024;[Epub] CrossRef
Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis Xin Zhang, Jiangguo Li, Li Jiang, Yuexia Deng, Licheng Wei, Xing Li Clinical and Experimental Medicine.2024;[Epub] CrossRef
The Metabolomic Footprint of Liver Fibrosis Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle Cells.2024; 13(16): 1333. CrossRef
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model Marwa Matboli, Ibrahim Abdelbaky, Abdelrahman Khaled, Radwa Khaled, Shaimaa Hamady, Laila M. Farid, Mariam B. Abouelkhair, Noha E. El-Attar, Mohamed Farag Fathallah, Manal S. Abd EL Hamid, Gena M. Elmakromy, Marwa Ali Lipids in Health and Disease.2024;[Epub] CrossRef
Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH Anja Schmidt-Christensen, Gustaw Eriksson, William M. Laprade, Behnaz Pirzamanbein, Maria Hörnberg, Kajsa Linde, Julia Nilsson, Mark Skarsfeldt, Diana J. Leeming, Rajmund Mokso, Mariana Verezhak, Anders Dahl, Vedrana Dahl, Kristina Önnerhag, Massoud Rezae Scientific Reports.2024;[Epub] CrossRef
Polygala japonica Houtt.: A comprehensive review on its botany, traditional uses, phytochemistry, pharmacology, and pharmacokinetics Hai-Peng Tang, En-Lin Zhu, Qian-Xiang Bai, Shuang Wang, Zhi-Bin Wang, Meng Wang, Hai-Xue Kuang Fitoterapia.2024; 179: 106233. CrossRef
Chondroitin Sulfate from Halaelurus burgeri Skin Inhibits Hepatic Endoplasmic Reticulum Stress and Inflammation, and Regulates Gut Microbiota Zhaocai Ren, Shang Gao, Shiwei Hu, Sichun Chen, Wei Jiang, Yaming Ge Molecular Nutrition & Food Research.2024;[Epub] CrossRef
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Miwa Kawanaka, Yoshihiro Kamada, Hirokazu Takahashi, Michihiro Iwaki, Ken Nishino, Wenli Zhao, Yuya Seko, Masato Yoneda, Yoshihito Kubotsu, Hideki Fujii, Yoshio Sumida, Hirofumi Kawamoto, Yoshito Itoh, Atsushi Nakajima, Takeshi Okanoue, Takumi Kawaguchi, Gastro Hep Advances.2024; 3(8): 1120. CrossRef
Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef
MASLD: predictive value for liver-related events and extra-hepatic complications Mohamad Jamalinia, Amedeo Lonardo Expert Review of Gastroenterology & Hepatology.2024; 18(11): 685. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean‐Francois Gautier, Angélique Brzustowski, Pierre Bedossa, Laurent Castera, Stanislas Pol, Dominique Valla Alimentary Pharmacology & Therapeutics.2023; 58(9): 888. CrossRef
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B” Soon Kyu Lee The Korean Journal of Gastroenterology.2025; 85(3): 245. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Exploration of Digestive Diseases.2024; : 175. CrossRef
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Victor Pântea, Gheorge Placinta, Scott J. Cotler, Andrew Vaillant, Harel Dahari Hepatology Communications.2023;[Epub] CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus Daniel G. Sausen, Oren Shechter, William Bietsch, Zhenzhen Shi, Samantha M. Miller, Elisa S. Gallo, Harel Dahari, Ronen Borenstein International Journal of Molecular Sciences.2022; 23(24): 15973. CrossRef
Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Clin Mol Hepatol 2022;28(1):77-90. Published online November 5, 2021
Background/Aims We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.
Methods The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.
Results Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).
Conclusions We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.
Preclinical studies on the antitumor and non‐toxic effect of combining pirfenidone with vinorelbine and carboplatin in non‐small cell lung cancer Helena Branco, Catarina A. Rodrigues, Júlio Oliveira, Nuno Mendes, Catarina Antunes, Irina Amorim, Lúcio L. Santos, M. Helena Vasconcelos, Cristina P. R. Xavier International Journal of Cancer.2025; 156(9): 1756. CrossRef
Phase-dependent hepatotoxicity of Aluminum oxide nanoparticles mediated through the intestinal microbiota Mingshu Li, Fuchang Deng, Li Dong, Xiaona Wang, Haiyan Jiang, Siyu Yao, Yuanyuan Chen, Lian Duan, Huamao Du, Guangqiu Qin, Song Tang Environment International.2025; 198: 109398. CrossRef
Parenclitic network mapping predicts survival in critically ill patients with sepsis Emily Ito, Tope Oyelade, Matthew Wikner, Jinyuan Liu, Watjana Lilaonitkul, Ali R. Mani Physiological Reports.2025;[Epub] CrossRef
The role of urea in pathological conditions O.B. Kvasnytska, A.I. Gozhenko, D.D. Ivanov, O.O. Popadynets KIDNEYS.2025; 14(3): 251. CrossRef
An RFH-NPT-based nomogram for predicting the long-term survival of liver cirrhosis patients: a multicenter study Chengbin Zhu, Yuchao Wu, Fulian Zhao, Ruojing Wang, Qijuan Zang, Zhe Jiao, Yage Zhu, Taotao Yan, Juan Du, Li Zhu, Weimin Li, Yongqin Li, Qing Fan, Anping Wu, Xiaodan Liu, Dianzu Liu, Xianmei Tang, Xiaoxiao Xu, Huaying Liao, Yu Li, Yingren Zhao, Yingli He, European Journal of Clinical Nutrition.2025;[Epub] CrossRef
Colchicine induces developmental defects and renal toxicity in zebrafish by upregulating the oxidative stress Fang Chen, Haiyan Wei, Dalong Liao, Yong Huang, Yijian Chen, Huiqiang Lu, Rong Xu Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology.2025; 298: 110328. CrossRef
Neurological alterations in adult female rats developmentally exposed to a glyphosate-based herbicide: Potential role of the immune system Cristina Eugenia Gallegos, Mariana Bartos, Fernanda Gumilar, Diego Nicolás Nabaes Jodar, Ileana Lencinas, Cristina Bras, Betina Noemí García, Jorge Andrés Delbés, Sergio Dominguez, Carlos Javier Baier Toxicology.2025; 518: 154279. CrossRef
Inverse Association Between METS-IR and Lung Cancer Risk: The Role of BMI in a Nationwide Korean Cohort Bo-Kyung Shine, In Hwa Jeong, Minkook Son, Bongjo Kim, Sang Yi Moon, Jong Yoon Lee, Hye Ryeon Kim, Seok Jae Huh Cancers.2025; 17(23): 3727. CrossRef
ULTRASONOGRAPHIC INDICATORS OF THE KIDNEYS IN COMBINED LIVER AND KIDNEY PATHOLOGY IN DOGS V. Rudyashko Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology.2025; 26(2): 216. CrossRef
Advances in Electrochemical Urea Biosensors: Trends and Future Prospects Samar Shurbaji, Arshad Khan, Mohammad K. Hassan, Amine Bermak, Wen‐Di Li, Kabir H Biswas, Bo Wang Advanced Sensor Research.2025;[Epub] CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient‐Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins Mona Mansouri, Astha Lamichhane, Dola Das, Federico Aucejo, Hossein Tavana, Nic D. Leipzig Advanced Biology.2024;[Epub] CrossRef
The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection Nathan E. Timbrell British Journal of Biomedical Science.2024;[Epub] CrossRef
The Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection Anwar Aiad Gaber, Jawad Kadhum Muraih Biomedical and Pharmacology Journal.2024; 17(1): 461. CrossRef
Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats Serdar Vanli, Firuze Kurtoglu, Beyza S. Alan, Gokhan Akcakavak, Ozgur Ozdemir Toxicology Mechanisms and Methods.2024; 34(7): 750. CrossRef
Association of blood urea nitrogen with all-cause and cardiovascular mortality in hyperlipidemia: NHANES 1999–2018 Jing Shen, Zhen Wang, Yong Liu, Tao Wang, Xiao-Yu Wang, Xin-Hui Qu, Zhi-Ping Chen, Xiao-Jian Han Lipids in Health and Disease.2024;[Epub] CrossRef
Association between serum vitamin D status and severity of liver cirrhosis: implications for therapeutic targeting in Nigerian patients Winnifred Njideka Adiri, Bruno Basil, Chinwe Philomena Onyia, Promise Asogwa, Oluchi Joy Ugwuanyi, Olive Obienu, Uchenna Nkemdilim Ijoma, Slyvester Chuks Nwokediuko BMC Gastroenterology.2024;[Epub] CrossRef
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong Hepatology.2023; 77(2): 573. CrossRef
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, Henry Lik‐Yuen Chan, Stephen Lam Chan, Alice Pik‐Shan Kong, Grace Lai‐Hung Wong, Vinc Alimentary Pharmacology & Therapeutics.2023; 57(10): 1103. CrossRef
Effects of the in-utero dicyclohexyl phthalate and di-n-hexyl phthalate administration on the oxidative stress-induced histopathological changes in the rat liver tissue correlated with serum biochemistry and hematological parameters Duygu Aydemir, Mufide Aydogan-Ahbab, Nurhayat Barlas, Nuriye Nuray Ulusu Frontiers in Endocrinology.2023;[Epub] CrossRef
A comparative multi-level toxicity assessment of carbon-based Gd-free dots and Gd-doped nanohybrids from coffee waste: hematology, biochemistry, histopathology and neurobiology study Halyna Kuznietsova, Natalia Dziubenko, Konstantin Paliienko, Natalia Pozdnyakova, Natalia Krisanova, Artem Pastukhov, Tetiana Lysenko, Marina Dudarenko, Valeriy Skryshevsky, Vladimir Lysenko, Tatiana Borisova Scientific Reports.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Effects of 4G mobile phone radiation exposure on reproductive, hepatic, renal, and hematological parameters of male Wistar rat Rohit Gautam, Sonali Pardhiya, Jay Prakash Nirala, Priyanka Sarsaiya, Paulraj Rajamani Environmental Science and Pollution Research.2023; 31(3): 4384. CrossRef
Is lean non-alcoholic fatty liver disease a distinct entity? Huapeng Lin, Vincent Wai-Sun Wong Hepatology International.2022; 16(2): 254. CrossRef
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Luisa Fürschuß, Florian Rainer, Angela Horvath, Vanessa Stadlbauer Liver International.2022; 42(7): 1702. CrossRef
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Suprabhat Giri, Shivaraj Afzalpurkar, Sunil Kasturi, Dhiraj Agrawal Liver International.2022; 42(7): 1700. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong
Clin Mol Hepatol 2021;27(3):499-509. Published online February 26, 2021
Background/Aims Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients.
Methods Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort.
Results 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70–0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted.
Conclusion A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
Citations
Citations to this article as recorded by
Liver elastography-based risk score for predicting hepatocellular carcinoma risk Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song JNCI: Journal of the National Cancer Institute.2025; 117(4): 761. CrossRef
Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study Yixin Hou, Jianguo Yan, Ke Shi, Xiaoli Liu, Fangyuan Gao, Tong Wu, Peipei Meng, Min Zhang, Yuyong Jiang, Xianbo Wang OncoTargets and Therapy.2024; Volume 17: 215. CrossRef
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults Xue Cong, Shuyao Song, Yingtao Li, Kaiyang Song, Cameron MacLeod, Yujie Cheng, Jun Lv, Canqing Yu, Dianjianyi Sun, Pei Pei, Ling Yang, Yiping Chen, Iona Millwood, Shukuan Wu, Xiaoming Yang, Rebecca Stevens, Junshi Chen, Zhengming Chen, Liming Li, Christia BMC Medicine.2024;[Epub] CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim Hepatology Communications.2023; 7(2): e0011. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi, Hepatology.2023; 77(5): 1746. CrossRef
Prognostic Significance of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score in Hepatocellular Carcinoma Jing Zhou, Daofeng Yang Journal of Hepatocellular Carcinoma.2023; Volume 10: 821. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program Supinya Sono, Jirayu Sae-Chan, Apichat Kaewdech, Naichaya Chamroonkul, Pimsiri Sripongpun, Jason T. Blackard PLOS ONE.2022; 17(6): e0270458. CrossRef
The Age, Gamma-Glutamyl Transpeptidase and Platelet Index: A Novel Noninvasive Model for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Liver Cirrhosis Kai Liu, Zeyu Huang, Suhua Yang, Lin Lin, Shuqin Zheng, Xiujun Zhang, Yuan Xue, Weibin Xie Journal of Hepatocellular Carcinoma.2022; Volume 9: 1057. CrossRef
Surveillance for hepatocellular carcinoma: It is time to move forward Bo Hyun Kim, Yuri Cho, Joong-Won Park Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status? Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2021; 27(3): 448. CrossRef
Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter Jimmy Che-To Lai, Anna S.F. Lok Hepatology.2026; 83(1): 11. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States Kevin Pak, Ryan Sachar, Sammy Saab Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Wen-Juei Jeng, Grace Lai-Hung Wong Hepatology Communications.2023; 7(3): e0060. CrossRef
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(3): 794. CrossRef
A global investment case for hepatitis B elimination: a modelling study Christopher P Seaman, Phillip Luong, Yinzong Xiao, Romesh Abeysuriya, Jess Howell, Margaret Hellard, Nick Scott The Lancet Gastroenterology & Hepatology.2023; 8(10): 932. CrossRef
Correlation between contrast-enhanced ultrasound perfusion parameters and EphB4 expression in hepatocellular carcinoma lesions Chen-ZhuoYa Sheng, Gen-Xin Yao, Xin-Rong Zhang, Dong Li World Chinese Journal of Digestology.2021; 29(18): 1084. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Although it has become one of the leading causes of cirrhosis and hepatocellular carcinoma in the Western world, the proportion of NAFLD patients developing these complications is rather small. Therefore, current guidelines recommend noninvasive tests for the initial assessment of NAFLD. Among the available non-invasive tests, transient elastography by FibroScan® (Echosens, Paris, France) is commonly used by hepatologists in Europe and Asia, and the machine has been introduced to the United States in 2013 with rapid adoption. Transient elastography measures liver stiffness and the controlled attenuation parameter simultaneously and can serve as a one-stop examination for both liver steatosis and fibrosis. Liver stiffness measurement also correlates with clinical outcomes and can be used to select patients for varices screening. Although obesity is a common reason for measurement failures, the development of the XL probe allows successful measurements in the majority of obese patients. This article reviews the performance and limitations of transient elastography in NAFLD and highlights its clinical applications. We also discuss the reliability criteria for transient elastography examination and factors associated with false-positive liver stiffness measurements.
Citations
Citations to this article as recorded by
Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria Eline C. B. Eskes, Laura van Dussen, Marion M. M. G. Brands, Frédéric M. Vaz, Johannes M. F. G. Aerts, André B. P. van Kuilenburg, Barbara Sjouke, Carla E. M. Hollak Journal of Inherited Metabolic Disease.2025;[Epub] CrossRef
Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma Mohamed El-Kassas, Heba A. Othman, Mohamed Elbadry, Khalid Alswat, Yusuf Yilmaz Journal of Clinical and Experimental Hepatology.2025; 15(1): 102415. CrossRef
The Loge GDR Was Strongly Associated with NAFLD as a Predictor in Normoalbuminuric Patients with Type 2 Diabetes Baolan Ji, Guanqi Gao, Hongyan Zhao, Jie Sheng, Xuan Ma, Shuwei Shi, Bo Ban Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 115. CrossRef
Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong Clinical Epidemiology.2025; Volume 17: 53. CrossRef
Development of a Fatty Liver Index Based on Real‐World Data Wenfeng Ding, Lanlan Liu, Wenjing Lu, Yingli Li, Jing Zhang, Cui Zhang, Yufei Wang, Xueping Ma, Xiaoli Yang iLABMED.2025; 3(1): 33. CrossRef
Machine Learning–Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease Jolie Boullion, Amanda Husein, Akshat Agrawal, Diensn Xing, Md Ismail Hossain, Md Shenuarin Bhuiyan, Oren Rom, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan The Journal of Clinical Endocrinology & Metabolism.2025; 110(11): e3866. CrossRef
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study Shuo Jiang, Fan Zhang, Hui Yang, Xue Han, Jieru Mao, Guojun Zheng, Yan Fan BMC Gastroenterology.2025;[Epub] CrossRef
The value of MR spectroscopy and MR elastography in assessing hepatic involvement of chronic visceral acid sphingomyelinase deficiency in adults Eline C.B. Eskes, Sandra A.M. van den Berg-Faaij, Nienke P.M. Wassenaar, Carla E.M. Hollak, Aart J. Nederveen, Barbara Sjouke Molecular Genetics and Metabolism.2025; 145(2): 109107. CrossRef
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai Ultrasonography.2025; 44(3): 189. CrossRef
Prospective Comparison of 2D-Shear Wave Elastography and Vibration-Controlled Transient Elastography in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Qingxin Li, Yanhang Gao, Dongxuan Wang, Xiaoxue Zhu, Jing Jia, Lili Liu, Huining Tian, Lishuang Wang, Yingwen Zhang, Dezhi Zhang Academic Radiology.2025; 32(9): 5100. CrossRef
Hepatic fibrosis in morbidly obese patients: fibroscan accuracy Maged Tharwat Elghannam, Moataz Hassan Hassanien, Ahmed Aly ELRay, Hoda Mohamed Abu-Taleb, Yosry Abdelrahman Ameen, Gamal Mohammed ELattar, Emad Abdelwahab Turky, Mohammed Darwish ELTalkawy Exploration of Digestive Diseases.2025;[Epub] CrossRef
Role of liver transient elastography in detecting cirrhosis with esophageal and gastric varices and evaluating variceal severity Chaozhi Wang BMC Gastroenterology.2025;[Epub] CrossRef
Attenuation Based Quantitative Evaluation of Hepatic Steatosis Using US: Current Status and Future Perspective Dong Ho Lee Journal of the Korean Society of Radiology.2025; 86(3): 321. CrossRef
Perturbation solution for second-harmonic generation in focused shear wave beams in soft solids Philip G. Kaufinger, John M. Cormack, Kyle S. Spratt, Mark F. Hamilton Wave Motion.2025; 139: 103595. CrossRef
Prevalence of Hepatic Steatosis and Fibrosis in Asian Indian Individuals with Type 2 Diabetes Khandhulwa Chandramouli Bhuvanesswar, Brijendra Kumar Srivastava, Anandakumar Amutha, Varun Damle, Aswin Krishna, Prasanna Kumar Gupta, Phillips Routray, Dhanasekaran Killivalavan, Saravanan Jebarani, Ulagamathesan Venkatesan, Rosette James Chakkalakal, Diabetes Therapy.2025; 16(9): 1797. CrossRef
Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study Hanan M Nafeh, Nourhan M Abbas, Mohamed A El-Mokhtar, Hebatallah M. Hassan, Sahar M Hassany The Egyptian Journal of Internal Medicine.2025;[Epub] CrossRef
Impact of genotyping (PTPN2, rs2542151) and (MBOAT7, rs641738) in prediction of fibrosis in Metabolic dysfunction- associated steatotic liver disease’ patients Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Zeinab A. Kasemy, Ehab Darwish, Asmaa Mosbeh, Ayman A. Sakr, Hanaa M. Elgazzar, Mervat Abdelkareem, Mai Abozeid, Shimaa K. Zewain, Hanan M. Bedair, Sabry M. Abdelmageed Frontiers in Endocrinology.2025;[Epub] CrossRef
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson JMIR Cardio.2025; 9: e72074. CrossRef
DC09, Derivative of 3‐(2‐hydroxy‐5‐methoxyphenyl)‐1‐(5‐methylfuran‐2‐yl)prop‐2‐en‐1‐one Attenuates Nonalcoholic Fatty Liver Disease by Targeting PI3K/Akt Pathway: Insights From In‐Vivo Zebrafish Model and In‐Vitro HepG2 Cell Santhanam Sanjai Dharshan, B. Haridevamuthu, Karthikeyan Ramamurthy, B. Aswinanand, Dhivya Loganathan Sumathi, Ilavenil Soundharrajan, Mansour K. Gatasheh, S. Karthick Raja Namasivayam, Kathiravan Muthu Kumaradoss, Jesu Arockiaraj Journal of Biochemical and Molecular Toxicology.2025;[Epub] CrossRef
Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective Eri G. Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Surabhi, Srinivasa R. Prasad, Venkata S. Katabathina RadioGraphics.2025;[Epub] CrossRef
Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li Biomarkers in Medicine.2025; 19(23): 1239. CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Kolbrun Sveinsdottir, Ari Pall Isberg, Bartosz Dobies, Gudlaug Erla Akerlie Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundu JMIR Cardio.2024; 8: e52576. CrossRef
Focused Shear Wave Beam Propagation in Tissue-Mimicking Phantoms John M. Cormack, Yu-hsuan Chao, Branch T. Archer, Kang Kim, Kyle S. Spratt, Mark F. Hamilton IEEE Transactions on Biomedical Engineering.2024; 71(2): 621. CrossRef
Development of Cost-Effective Fatty Liver Disease Prediction Models in a Chinese Population: Statistical and Machine Learning Approaches Liang Zhang, Yueqing Huang, Min Huang, Chun-Hua Zhao, Yan-Jun Zhang, Yi Wang JMIR Formative Research.2024; 8: e53654. CrossRef
Exploring the link: magnesium intake and hepatic steatosis in Americans Xingxing Chen, Liying Fu, Zhongxin Zhu, Yunchao Wang Frontiers in Nutrition.2024;[Epub] CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL Bilal A. Mir, Brij Sharma, Rajesh Sharma, Vishal Bodh, Ashish Chauhan, Tahir Majeed, Inaamul Haq, Neetu Sharma, Dikshant Sharma Journal of Clinical and Experimental Hepatology.2024; 14(5): 101398. CrossRef
Comparative value of controlled attenuation (CAPc) and continuous controlled attenuation (CAP) parameters for different stages of non-alcoholic fatty liver disease A. A. Goncharov, A. N. Sasunova, V. A. Isakov Experimental and Clinical Gastroenterology.2024; (2): 55. CrossRef
Exploring the association between dietary fiber intake and hepatic steatosis: insights from NHANES Xingxing Chen, Liying Fu, Zhongxin Zhu, Yunchao Wang BMC Gastroenterology.2024;[Epub] CrossRef
Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities Eugene Han, Yong-ho Lee, Sang Hoon Ahn, Bong-Soo Cha, Seung Up Kim, Byung-Wan Lee Gut and Liver.2024; 18(3): 509. CrossRef
Associations between allostatic load and hepatic steatosis and liver fibrosis: evidence from NHANES 2017–2020 Zhikun Dai, Xiaohui Zhou BMC Public Health.2024;[Epub] CrossRef
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review Consolato M. Sergi International Journal of Molecular Sciences.2024; 25(15): 8462. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
Electrical and Viscoelastic Parameters of Erythrocytes as a Part of Diagnostic Models for Differentiating Fatty Liver Disease of Mixed Genesis from Non-Alcoholic and Alcohol-Related Fatty Liver Disease M. V. Kruchinina, M. F. Osipenko, M. V. Parulikova, A. A. Gromov Russian Journal of Gastroenterology, Hepatology, Coloproctology.2024; 34(3): 38. CrossRef
Diagnostic models for differentiating fatty liver disease of alcohol and non-alcoholic genesis M. V. Kruchinina, M. F. Osipenko, M. V. Parulikova, A. V. Belkovets, E. V. Kruchinina Meditsinskiy sovet = Medical Council.2024; (15): 80. CrossRef
Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test Terence N Moyana World Journal of Gastroenterology.2024; 30(42): 4576. CrossRef
Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease Amedeo Lonardo, Stefano Ballestri, Gyorgy Baffy, Ralf Weiskirchen Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross‐Sectional Study Delphine Napon‐Zongo, Jeoffray Diendere, Armel M. Sanou, Abou Coulibaly, Abdoulaye Dera, Nina G. M. Ouattara, Augustin N. Zeba, Seni Kouanda JGH Open.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Жирные кислоты мембран эритроцитов как биомаркеры неалкогольной жировой болезни печени у мужчин М. В. Кручинина, М. В. Паруликова, Н. Е. Першина, Э. В. Кручинина Ateroscleroz.2023; 18(4): 362. CrossRef
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018 Julia Y. Payne, Naim Alkhouri, Phuc Le, Michael B. Rothberg, Prido Polanco, Celine Sakkal, Srinivasan Dasarathy Hepatology Communications.2023; 7(1): e0019. CrossRef
Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Nila Jambulingam, Roberta Forlano, Benjamin Preston, Benjamin H. Mullish, Greta Portone, Yama Baheer, Michael Yee, Robert D. Goldin, Mark R. Thursz, Pinelopi Manousou International Journal of Molecular Sciences.2023; 24(4): 3563. CrossRef
Special Population Ajay Duseja, Arka De, Vincent Wong Clinics in Liver Disease.2023; 27(2): 451. CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial Lygia N. Barroso, Jessica Salarini, Nathalie Carvalho Leite, Cristiane A. Villela-Nogueira, Alberto Dávalos, Maria das Graças Tavares Carmo, Wilza Arantes Ferreira Peres Clinical Nutrition ESPEN.2023; 57: 117. CrossRef
B-mode shear wave elastography can be an alternative method to vibration-controlled transient elastography according to a moderate-scale population study Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Ryo Yano, Kana Hirooka, Makoto Morita, Yusuke Imai, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa Journal of Medical Ultrasonics.2023; 50(4): 473. CrossRef
Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register Alice Pik-Shan Kong, Eric Siu-Him Lau, Chun-Kwan O, Andrea On-Yan Luk, Terry Cheuk-Fung Yip, Elaine Yee-Kwan Chow, Raymond Kwok, Hye Won Lee, Grace Lai-Hung Wong, Ronald Ching-Wan Ma, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Juliana Chung-Ngor Chan Diabetes Research and Clinical Practice.2023; 202: 110825. CrossRef
Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis Run Zhou, Luping Yang, Binbin Zhang, Yunpeng Gu, Tingting Kong, Wei Zhang, Lei Sun, Chunlan Liu, Ningjia Kong, Jie Li, Junping Shi Journal of Viral Hepatitis.2023; 30(10): 793. CrossRef
Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch Yan Liao, Lei Liu, Jiayao Yang, Xiaoli Zhou, Xiaoli Teng, Yixi Li, Ying Wan, Jian Yang, Zhaohong Shi Scientific Reports.2023;[Epub] CrossRef
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease Johnny T. K. Cheung, Xinrong Zhang, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Huapeng Lin, Guanlin Li, Howard Ho‐Wai Leung, Jimmy Che‐To Lai, Sanjiv Mahadeva, Nik Raihan Nik Mustapha, Xiao‐Dong Wang, Wen‐Yue Liu, Vincent Wai‐Sun Wong, Wah‐Kheong Chan, Mi Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1194. CrossRef
Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease Alexey A. Goncharov, Armida N. Sasunova, Vladimir I. Pilipenko, Vasily A. Isakov Terapevticheskii arkhiv.2023; 95(8): 641. CrossRef
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis Xinrong Zhang, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Stephen Lam Chan, Alice Pik-Shan Kong, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Hepatology.2023; 78(6): 1816. CrossRef
Low Relative Handgrip Strength Is Associated with a High Risk of Non-Alcoholic Fatty Liver Disease in Italian Adults: A Retrospective Cohort Study Samantha Maurotti, Roberta Pujia, Elisa Mazza, Maria Francesca Pileggi, Franco Arturi, Maria Grazia Tarsitano, Tiziana Montalcini, Arturo Pujia, Yvelise Ferro Applied Sciences.2023; 13(22): 12489. CrossRef
Non-Invasive Diagnostic of NAFLD in Type 2 Diabetes Mellitus and Risk Stratification: Strengths and Limitations Alina Boeriu, Daniela Dobru, Crina Fofiu Life.2023; 13(12): 2262. CrossRef
Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey Thomas Forst, Isabel Botz, Matthias Berse, Stephan Voswinkel, Mares-Elaine Strempler, Sybille Baumann, Maria Marinez Journal of Diabetes & Metabolic Disorders.2023; 23(1): 999. CrossRef
Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Jimmy Che-To Lai, Lilian Yan Liang, Grace Lai-Hung Wong Gastroenterology Report.2023;[Epub] CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Diagnostic Performance of 2-D Shear Wave Elastography on the Evaluation of Hepatic Fibrosis with Emphasis on Impact of the Different Region-of-Interest Methods Eun Mi Kim, Ji-Won Park, Sang Min Lee, Min-Jeong Kim, Hong Il Ha, Sung-Eun Kim, Eun Soo Kim, Young Chul Kim, Kwanseop Lee Ultrasound in Medicine & Biology.2022; 48(2): 198. CrossRef
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad, Arun J. Sanyal Diabetes & Metabolism.2022; 48(2): 101281. CrossRef
Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors Sunyoung Lee, Kyoung Won Kim, So Yeon Kim, Nieun Seo, Gi-Won Song, Sung-Gyu Lee Ultrasonography.2022; 41(1): 164. CrossRef
Transient Elastography–Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States Aynur Unalp-Arida, Constance E. Ruhl Clinical Gastroenterology and Hepatology.2022; 20(4): e808. CrossRef
Non-invasive tests of non-alcoholic fatty liver disease Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Chinese Medical Journal.2022; 135(5): 532. CrossRef
Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Young Jang, Soo Young Park, Hyun Woong Lee, Chun Kyon Lee, Seung Up Kim Frontiers in Medicine.2022;[Epub] CrossRef
Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease Wen Guo, Xin Zhao, Mengyuan Miao, Xiuru Liang, Xiaona Li, Pei Qin, Jing Lu, Wenfang Zhu, Juan Wu, Chen Zhu, Nianzhen Xu, Qun Zhang Frontiers in Nutrition.2022;[Epub] CrossRef
Vibration-controlled Transient Elastography in NAFLD: Review Study Hasan Ozkan, Abdullah M Ozercan Euroasian Journal of Hepato-Gastroenterology.2022; 12(S1): S41. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
DETERMINANTS OF SIGNIFICANT HEPATIC FIBROSIS IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN SOUTH INDIA. A V Ramya, P Thirumal INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2022; : 24. CrossRef
Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization David T. Fetzer, Ivan M. Rosado-Mendez, Michael Wang, Michelle L. Robbin, Arinc Ozturk, Keith A. Wear, Juvenal Ormachea, Timothy A. Stiles, J. Brian Fowlkes, Timothy J. Hall, Anthony E. Samir Radiology.2022; 305(2): 265. CrossRef
The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population Haofei Hu, Yong Han, Changchun Cao, Yongcheng He Journal of Translational Medicine.2022;[Epub] CrossRef
Myocyte Enhancer Factor 2A Contributes to the TGF-β1-Mediated Cholangiocyte Epithelial to Mesenchymal Transition and Senescence in Cholestatic Liver Fibrosis Guangxi Zhou, Fei Hou, Heng He, Yuan Xue, Yibo Wang, Xueying Chen, Fengqin Zhu Frontiers in Bioscience-Landmark.2022;[Epub] CrossRef
Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter Sun Kyung Jeon, Jeong Min Lee, Ijin Joo Ultrasound in Medicine & Biology.2021; 47(3): 438. CrossRef
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective Gwyneth Soon, Aileen Wee Clinical and Molecular Hepatology.2021; 27(1): 44. CrossRef
Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography Jae Hyon Park, Nieun Seo, Yong Eun Chung, Seung Up Kim, Yung Nyun Park, Jin-Young Choi, Mi-Suk Park, Myeong-Jin Kim European Radiology.2021; 31(7): 4813. CrossRef
Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE) Wayne Eskridge, John M. Vierling, Wayne Gosbee, Gabriella A. Wan, May-Linh Hyunh, Henry E. Chang, Daisuke Tokuhara PLOS ONE.2021; 16(11): e0260320. CrossRef
A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery Shirley Yuk-Wah Liu, Vincent Wai-Sun Wong, Simon Kin-Hung Wong, Grace Lai-Hung Wong, Carol Man-sze Lai, Candice Chuen-Hing Lam, Sally She-Ting Shu, Henry Lik-Yuen Chan, Enders Kwok-Wai Ng Scientific Reports.2021;[Epub] CrossRef
Ultrasound Elastography in Liver Tissue: Current Status Zhang, MD Mingzhu, Ding, MD Zhaoyan, Niu, MD Xiaoyan, Gao, MD Yuxiu, Zhao, MD Cheng ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY.2021; 5(3): 197. CrossRef
Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications Duanghathai Pasanta, Khin Thandar Htun, Jie Pan, Montree Tungjai, Siriprapa Kaewjaeng, Hongjoo Kim, Jakrapong Kaewkhao, Suchart Kothan Diagnostics.2021; 11(5): 842. CrossRef
Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications T. Hydes, E. Brown, A. Hamid, A.C. Bateman, D.J. Cuthbertson Clinical Therapeutics.2021; 43(9): 1505. CrossRef
Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version L. B. Lazebnik, E. V. Golovanova, S. V. Turkina, K. L. Raikhelson, S. V. Okovityy, O. M. Drapkina, I. V. Maev, A. I. Martynov, G. E. Roitberg, O. V. Khlynova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, A. O. Bue Experimental and Clinical Gastroenterology.2021; 1(1): 4. CrossRef
Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg V. P. Kovyazina, K. L. Raikhelson, M. K. Prashnova, E. V. Pazenko, L. K. Palgova, E. A. Kondrashina Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(1): 31. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
Diagnostic Performance of Noninvasive Methods for Liver Biopsy by Fibroscan in Pediatric Ghobad Heidari, Farzaneh Motamed, Bita Heirati, Parisa Rahmani Journal of Child Science.2021; 11(01): e55. CrossRef
The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics James Neuberger, Owen Cain Hepatic Medicine: Evidence and Research.2021; Volume 13: 59. CrossRef
Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy Han Ah Lee, Beom Kyung Kim, Seung Up Kim Journal of Hepatology.2020; 73(1): 222. CrossRef
A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn Journal of Liver Cancer.2020; 20(1): 53. CrossRef
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease Janae Wentong Wai, Charmaine Fu, Vincent Wai-Sun Wong Journal of Gastroenterology.2020; 55(8): 731. CrossRef
High body mass index hinders fibrosis improvement in patients receiving long‐term tenofovir therapy in hepatitis B virus‐related cirrhosis Young Eun Chon, Kyu Sik Jung, Yeonjung Ha, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Sang Hoon Ahn, Do Young Kim, Kwang‐Hyub Han, Jun Yong Park Journal of Viral Hepatitis.2020; 27(11): 1119. CrossRef
Application of Baveno Criteria and Modified Baveno Criteria with Shear-wave Elastography in Compensated Advanced Chronic Liver Disease Seong Hee Kang, Soon Koo Baik, Moon Young Kim Journal of Korean Medical Science.2020;[Epub] CrossRef
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography Monica Lupsor-Platon, Teodora Serban, Alexandra-Iulia Silion, Alexandru Tirpe, Mira Florea Cancers.2020; 12(10): 2778. CrossRef
Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis Anurag Mishra, Tamara R. Castañeda, Erik Bader, Bettina Elshorst, Sheila Cummings, Petra Scherer, Dinesh S. Bangari, Claudia Loewe, Herman Schreuder, Christoph Pöverlein, Mike Helms, Seth Jones, Gernot Zech, Thomas Licher, Michael Wagner, Manfred Schudok, Advanced Science.2020;[Epub] CrossRef
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study Omesh Goyal, Sahil Nohria, Prerna Goyal, Jaskirat Kaur, Sarit Sharma, Ajit Sood, Rajoo Singh Chhina Scientific Reports.2020;[Epub] CrossRef
Effects of Ademetionine on Liver Fibrosis, Level of Pentraxin-3 and Metabolic Indicators in Patients with Comorbid Course of Non-alcoholic Liver Disease and Arterial Hypertension T. N. Alexandrova, O. Ya. Babak Ukraïnsʹkij žurnal medicini, bìologìï ta sportu.2020; 5(6): 95. CrossRef
East Asia expert opinion on treatment initiation for chronic hepatitis B Jia‐Horng Kao, Tsung‐Hui Hu, Jidong Jia, Masayuki Kurosaki, Young‐Suk Lim, Han‐Chieh Lin, Dong Hyun Sinn, Yasuhito Tanaka, Vincent Wai‐Sun Wong, Man‐Fung Yuen Alimentary Pharmacology & Therapeutics.2020; 52(10): 1540. CrossRef
Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Hyung Jong Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Sun Lee, Seung Up Kim, Young Dae Kim Cerebrovascular Diseases.2020; 49(5): 474. CrossRef
First
Prev
